De Novo Lipogenesis Inhibitors: As the other innovative agents for therapy of Metabolic Diseases (Obesity, NAFLD/NASH, CVD) - A narrative Review
good therapeutic approach. Although numerous hurdles anticipated regarding effectiveness, selectiveness besides safety variable newer classes of synthetic DNL hampering agents have reached clinical stage generation…

